CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
Abstract. Chimeric antigen receptor (CAR)-T-cell therapy has achieved significant success in the treatment of hematologic malignancies. However, treatment-related toxicity and side effects remain the major drawbacks. As an important effector cell in innate immunity, natural killer (NK) cells exert s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health
2019-10-01
|
| Series: | Blood Science |
| Online Access: | http://journals.lww.com/10.1097/BS9.0000000000000028 |
| _version_ | 1828872956792537088 |
|---|---|
| author | Kai-lin Xu Hai Cheng |
| author_facet | Kai-lin Xu Hai Cheng |
| author_sort | Kai-lin Xu |
| collection | DOAJ |
| description | Abstract. Chimeric antigen receptor (CAR)-T-cell therapy has achieved significant success in the treatment of hematologic malignancies. However, treatment-related toxicity and side effects remain the major drawbacks. As an important effector cell in innate immunity, natural killer (NK) cells exert strong antitumor functions and have better application prospects in the immunotherapy of hematologic malignancies. Compared with T cells, NK cells exhibit several advantages such as MHC-independent recognition. CAR-modified NK (CAR-NK) cells may exhibit a better ability of killing tumor cells. Herein, we review mainly preclinical data related to the development of CAR-NK cells in treating blood cancers. |
| first_indexed | 2024-12-13T07:05:18Z |
| format | Article |
| id | doaj.art-1b222d94deae40189f132f253989c902 |
| institution | Directory Open Access Journal |
| issn | 2543-6368 |
| language | English |
| last_indexed | 2024-12-13T07:05:18Z |
| publishDate | 2019-10-01 |
| publisher | Wolters Kluwer Health |
| record_format | Article |
| series | Blood Science |
| spelling | doaj.art-1b222d94deae40189f132f253989c9022022-12-21T23:55:49ZengWolters Kluwer HealthBlood Science2543-63682019-10-011215616010.1097/BS9.0000000000000028201910000-00007CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizonKai-lin XuHai ChengAbstract. Chimeric antigen receptor (CAR)-T-cell therapy has achieved significant success in the treatment of hematologic malignancies. However, treatment-related toxicity and side effects remain the major drawbacks. As an important effector cell in innate immunity, natural killer (NK) cells exert strong antitumor functions and have better application prospects in the immunotherapy of hematologic malignancies. Compared with T cells, NK cells exhibit several advantages such as MHC-independent recognition. CAR-modified NK (CAR-NK) cells may exhibit a better ability of killing tumor cells. Herein, we review mainly preclinical data related to the development of CAR-NK cells in treating blood cancers.http://journals.lww.com/10.1097/BS9.0000000000000028 |
| spellingShingle | Kai-lin Xu Hai Cheng CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon Blood Science |
| title | CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon |
| title_full | CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon |
| title_fullStr | CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon |
| title_full_unstemmed | CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon |
| title_short | CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon |
| title_sort | car nk cell therapeutics for hematologic malignancies hope is on the horizon |
| url | http://journals.lww.com/10.1097/BS9.0000000000000028 |
| work_keys_str_mv | AT kailinxu carnkcelltherapeuticsforhematologicmalignancieshopeisonthehorizon AT haicheng carnkcelltherapeuticsforhematologicmalignancieshopeisonthehorizon |